Stocks & Indices Unverified First seen 2026-10-22 13:24 UTC

Biohaven stock jumps over 30% after FDA agrees to review troriluzole

Investor's Business Daily reported that Biohaven stock catapulted more than 30% early Thursday after the FDA said it would review the company's drug troriluzole. The post describes troriluzole as the company's embattled drug.

Why “Unverified”

Reported by Investor's Business Daily alone, with no second source or primary confirmation yet

1 independent source group across 1 post · evidence score 52/100. How labels work

What the sources claim

Biohaven stock rose more than 30% early Thursday after the FDA said it would review troriluzole.

“Biohaven stock catapulted more than 30% early Thursday after the FDA said it would review”
Investor's Business Daily
Troriluzole is described as the company's embattled drug.

“the company's embattled drug, troriluzole”
Investor's Business Daily

Sources

Investor's Business Daily newswire 2026-10-22 13:24 UTC
Why Biohaven Catapulted 30%-Plus — And Why It Might Not Be Done Sprinting

More in Stocks & Indices

All Stocks & Indices stories →

Summary and claims extracted by AI with prompt analyze-story@5 on 2026-10-22 13:30 UTC. Labels are computed from the sources, not by the model.